TERM OF APPROVAL

Release date: August 2009
Expiration date: August 31, 2010

PROGRAM OVERVIEW

Several landmark clinical studies have demonstrated the relationship
between type 2 diabetes and increased risk of both microvascular
and macrovascular complications. Optimal glycemic control is vital
to managing these risks in patients with type 2 diabetes. However,
recent estimates indicate that only 57% of type 2 diabetes patients
reach the American Diabetes Association glycemic target of A1C < 7%.

Historically, glycemic control efforts have emphasized achievement of A1C and fasting plasma glucose (FPG) targets. It has recently become increasingly evident that postprandial increases in blood glucose levels also contribute significantly to overall glycemic control and to the development of diabetes complications. Consequently, postprandial plasma glucose (PPG) control is receiving recognition as an essential therapeutic target for optimizing glycemic control in patients with type 2 diabetes. This publication series will explore the science of PPG and its contribution to glycemic control, and highlight recent and emerging therapies that address this important target.

INTENDED AUDIENCE

This program is intended for endocrinologists, diabetologists, and other healthcare professionals (HCPs) who frequently treat patients with type 2 diabetes.

LEARNING OBJECTIVES

After completing this issue, participants should be able to:

• List the mechanisms of action of dipeptidyl peptidase-4 (DPP-4) inhibitors, paying specific attention to how they affect PPG levels
• Discuss the clinical efficacy of DPP-4 inhibitors for the treatment of type 2 diabetes
• Describe the safety profile of DPP-4 inhibitors
• Explain how DPP-4 inhibitors can be incorporated into the treatment algorithm for type 2 diabetes

ACCREDITATION AND CREDIT DESIGNATION STATEMENTS

The Institute for Medical and Nursing Education, Inc (IMNE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

IMNE designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

DISCLOSURES

In compliance with the ACCME’s Standards for Commercial Support, it is the policy of IMNE to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals involved in
planning (eg, CME provider staff, faculty, and planners) are expected to disclose any significant financial relationships with commercial interests over the past 12 months. IMNE also requires that faculty identify and reference off-label or investigational use of pharmaceutical agents and medical devices.

In accordance with ACCME Standards for Commercial Support, parallel documents from other accrediting bodies, and IMNE policy, identification and resolution of conflict of interest have been made in the form of external peer review of educational content. The following disclosures have been made:

FACULTY

David D’Alessio, MD
Formal Advisor: Takeda Pharmaceuticals North America, Inc;
Merck & Co, Inc
Research Activities: Amylin Pharmaceuticals, Inc; Eli Lilly and Company; ETHICON, Inc
Consultant: Amylin Pharmaceuticals, Inc; MannKind Corporation

CME AND EDUCATIONAL PARTNER STAFF

Steve Weinman, RN
Executive Director
IMNE
Disclosures: Nothing to disclose

Amy Groves
Director, Program Development
IMNE
Disclosures: Nothing to disclose

Katie Fidanza
Program Development Executive
IMNE
Disclosures: Nothing to disclose

Megan Stephan, PhD
Freelance Science and Medical Writer
IMNE
Disclosures: Nothing to disclose

Robert Hash, MD
Texas A&M Health Science Center
College of Medicine
College Station, Texas
Dr Hash has nothing to disclose.

Martin Quan, MD
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California
Dr Quan has nothing to disclose.

DISCLAIMER

This activity is designed for HCPs for educational purposes. Information and opinions offered by the faculty/presenters represent their own viewpoints. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information.

While IMNE makes every effort to have accurate information presented, no warranty, expressed or implied, is offered. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is partially supported by an educational grant from Takeda
Pharmaceuticals North America, Inc.

METHOD OF OBTAINING CME CREDIT

CME credit/verification is offered upon successful completion of a posttest with a minimum passing score of 70%. CME certificates will be issued to participants after receipt of the CME registration form, evaluation form, and successfully completed posttest. For those taking the test and completing the evaluation online at www.webbasedCME.com, a printable certificate will be made available upon successful completion of the posttest.

Questions or comments can be addressed to steve.weinman@imne.com.

If you choose to apply for CME credit by mail or fax, please allow up to 12 weeks for issuance of CME credit.